|Healthcare Review: HealthStream, VIVUS, GenVec Inc., BG Medicine, Cempra Inc.|
|By Staff and Wire Reports|
|Tuesday, 28 May 2013 13:46|
HealthStream, Inc. (NASDAQ:HSTM) shares climbed 3.59% to $25.37 in the early hour. The company on April 22 announced that for fiscal 2013, it affirmed its previous guidance and anticipates consolidated revenues to grow between 20% to 22% over fiscal 2012. The Company anticipate revenue growth in the Learning & Talent Management segment to be in the 24% to 26% range and the Research segment's revenues to increase approximately eight to 10%. The Company anticipate operating income to be approximately 6% to 10% over fiscal 2012. Analysts were expecting the Company to report revenue of $126 million and EBIT of $14.57 million for fiscal 2013.
VIVUS, Inc.(NASDAQ:VVUS) shares gained 1.21% to $15. The company on May 16 announced the pricing of its offering of $220 million aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 (the "Notes") in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). VIVUS has granted to the initial purchasers a 30-day option to purchase up to an additional $30 million aggregate principal amount of the Notes. The offering is expected to close on or about May 21, 2013, subject to customary closing conditions.
GenVec Inc. (NASDAQ:GNVC) shares declined 36.10% to $0.460. The company on May 28 announced that on May 24 its board approved a plan of complete liquidation and dissolution of the company, saying that it is in the best interests of the company and its stockholders.
The company said, if the company's stockholders approve the Plan of Dissolution, that it plans to file a certificate of dissolution with the Delaware Secretary of State, complete the liquidation of the Company's assets, satisfy the Company's remaining obligations and make distributions to the Company's stockholders of any available liquidation proceeds.
BG Medicine, Inc. (NASDAQ:BGMD) shares gained 11.92% to $1.92. The Company, on May 28, announced the presentation of new clinical research data on the BGM Galectin-3® test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal. Among the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy which demonstrated the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients diagnosed with a form of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF).
Cempra Inc. (NASDAQ:CEMP) shares gained 9.40% to $7.80 in the morning hour. The company on May 28 announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Cempra with a five year contract valued up to $58 millionfor the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens. Solithromycin, Cempra's lead product candidate, is a fourth generation macrolide antibiotic in the fluoroketolide family that is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. The company will host a conference call and webcast at 8:30 a.m. EDT, tomorrow, May 29, to discuss the agreement.